Compositions and methods for in situ-forming gels for wound healing and tissue regeneration
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
United States Department of Veterans Affairs • Leland Stanford Junior University
MemberStanford UniversityStanford UniversityTodd Coleman is an associate professor of bioengineering at Stanford University. His research combines applied probability, physiology, and bioelectronics to develop methods and devices for monitoring and modulating nervous-system and other physiological activity, including brain and visceral-organ signals.
Todd Coleman is an associate professor of bioengineering at Stanford University. His research combines applied probability, physiology, and bioelectronics to develop methods and devices for monitoring and modulating nervous-system and other physiological activity, including brain and visceral-organ signals.
Abstract
Compositions and methods are provided for lamellar and defect reconstruction of corneal stromal tissue using supramolecular complexes that form a defined gel structure in situ. Such gels can serve as cellular or acellular matrices with or without certain encapsulated therapeutic factors to facilitate tissue regeneration such as multilayered re-epithelialization of wounded corneal stromal tissue.
Core Innovation
The disclosure describes flowable biomaterials that form a defined gel matrix on an ocular tissue area in situ and encapsulate cells for ocular wound repair and tissue regeneration. The biomaterials comprise polymers crosslinked through non-covalent linkages in a supramolecular structure that are reversible under shear. Crosslinking systems include Cucurbit[n]uril (CB[n], n=5-8 and 10) and adamantane moieties, or cucurbit[8]uril-based crosslinks formed through thiol-ene reactions between preassembled CB[8]·peptide ternary complexes and norbornenes grafted to a biopolymer.
The supramolecular hydrogel materials support cell encapsulation and ocular delivery while exhibiting shear-thinning, self-healing, and optical transmittance properties, remaining injectable after gelation. Embodiments describe light-initiated supramolecular networks crosslinking cell-adhesive biopolymers including gelatin-norbornene. Documented implementations evaluate cell-containing sulfated hyaluronic acid and linear hyaluronic acid hydrogels on corneal wounds, demonstrating corneal cell adhesion, viability, spreading, and wound-related outcomes.
Claims Coverage
The claim coverage identifies three independent claims covering three inventive features for flowable, cell-encapsulating biomaterials that form defined gel matrices on ocular tissue in situ.
Cucurbit[n]uril and adamantane crosslinked biomaterial
Claim 1 covers a flowable biomaterial that forms a defined gel matrix on an ocular tissue area in situ with encapsulated cells. A polymer is crosslinked through non-covalent linkages that are reversible under shear in a supramolecular structure, with Cucurbit[n]uril (CB[n], n=5-8 and 10) moieties on the first polymer and adamantane (Ad) moieties on the second polymer.
Cucurbit[8]uril-based peptide crosslinks
Claim 11 covers a flowable biomaterial that forms a defined gel matrix on an ocular tissue area in situ and encapsulates cells. Its cucurbit[8]uril-based crosslinks are formed via thiol-ene reactions between preassembled CB[8]·peptide ternary complexes and norbornenes grafted to a biopolymer, and are reversible under shear.
Light-initiated crosslinking with terminally specified peptide
Claim 14 covers a flowable biomaterial forming a defined gel matrix on an ocular tissue area in situ and encapsulating cells. It specifies CB[8]-based crosslinks formed via light-initiated thiol-ene reactions crosslinking a cell-adhesive biopolymer into a supramolecular hydrogel, using norbornenes grafted to a biopolymer and preassembled CB[8]·peptide ternary complexes where the peptide comprises an N-terminal phenylalanine and a C-terminal cysteine, with crosslinks reversible under shear.
The independent claims cover cell-containing flowable ocular biomaterials with shear-reversible supramolecular gel matrices, distinguishing Cucurbit[n]uril-adamantane systems from CB[8]-based peptide and norbornene systems, with claim 14 further specifying peptide termini and light-initiated supramolecular hydrogel formation.
Stated Advantages
The CB[8] hydrogels are described as optically favorable, shear-thinning, self-healing, and injectable after gelation.
The disclosed matrices support cell viability and distribution, reporting post-injection viability above 94% as well as sustained fibroblast viability and spreading over seven days.
The disclosure reports corneal-cell adhesion and wound-healing results with supramolecular hyaluronic acid gels.
Documented Applications
Formation of a defined, cell-encapsulating gel matrix on an ocular tissue area in situ.
Ocular wound repair and tissue regeneration using flowable, in-situ-forming supramolecular hydrogels.
Repair of corneal defects and application of cell-containing hydrogels to corneal wounds, including evaluation of sulfated hyaluronic acid and linear hyaluronic acid treatments.
Ocular delivery of corneal endothelial cells.
Interested in licensing this patent?